Imperial Brands faces litigation risk spanning product liability claims, government healthcare cost recovery lawsuits, and potential criminal enforcement actions, according to a February 2026 regulatory risk assessment.
The FTSE 100 tobacco company carries a 'major' severity rating for these legal exposures, with analysts assigning medium likelihood to the risk materializing. The assessment holds 70% confidence.
Product liability claims form the first litigation vector. Tobacco manufacturers across Europe face ongoing legal challenges over health impacts, with courts increasingly receptive to consumer protection arguments. Imperial Brands operates in branded tobacco goods and consumer products, exposing it to claims across multiple product lines.
Government healthcare cost recovery represents the second front. EU member states have pursued tobacco companies for public health expenditures tied to smoking-related illnesses. These suits seek billions in recovery costs, citing decades of healthcare spending on respiratory disease, cancer treatment, and cardiovascular conditions.
Criminal enforcement actions constitute the third risk category. Regulatory bodies have escalated scrutiny of tobacco industry practices, including marketing to minors, nicotine content disclosure, and cross-border tax compliance. The EU Tobacco Products Directive imposes strict manufacturing, presentation, and sale requirements, with criminal penalties for violations.
Imperial Brands reported full-year results amid this litigation environment. The company manufactures and distributes tobacco products across FTSE 100 markets, making it subject to both UK and EU regulatory frameworks.
The tobacco sector faces intensifying legal pressure as governments balance public health objectives against tax revenue from tobacco sales. Product liability doctrine has evolved to favor plaintiffs in consumer protection cases, while healthcare cost recovery suits gain traction in jurisdictions previously resistant to such claims.
Criminal enforcement has expanded beyond traditional areas into supply chain compliance and digital marketing practices. Regulatory agencies now coordinate cross-border investigations, increasing prosecution risk for multinational tobacco companies.
The medium likelihood rating reflects uncertainty in case outcomes and enforcement priorities, while the major severity classification indicates material financial impact if litigation proceeds unfavorably.